Frost & Sullivan Appoints Maz Khan to Lead Its Pharmaceutical Team in Australia

SYDNEY, Australia--(Business Wire)--
Frost & Sullivan has appointed Mr. Maz Khan as Director for its
Pharmaceutical team in Australia.

With current big pharma strategy seeming to be more focused in
chosen core areas of specialization like specialty pharmaceuticals and
biotech, rather than the traditional blockbuster approach, Australia
has a strong position as a significant research base. "Despite having
only 0.3 percent of the world's population and a pharmaceutical market
that is approximately 1.0 percent of the global market, Australia
contributes 2.5 percent towards the world's medical research and 2.9
percent to global scientific publications," says Jonathan Raja,
Director of Australia Healthcare Practice, Frost & Sullivan.

Mr. Raja added that "Australia is clearly one of the world's
preferred location to conduct global clinical trials, and as at
quarter four 2007, there were 50 Phase I trials, 153 Phase 2 trials,
262 Phase 3 and 65 Phase 4 trials being conducted here. However, with
the increasing patient base that needs treatment due to increased
prevalence and advances in diagnostics, the challenges of costs have
driven pharmacoeconomics to emerge as one of the vital research areas.
Communicating the cost-benefit of products is an important contributor
to commercial success and Frost & Sullivan foresees further increase
in use of pharmacoeconomic analyses, such as price threshold and
market uptake from the access population, as part of a comprehensive
to-market strategy."

"Maz Khan is a strong addition to the Australia Healthcare team,"
he said.

In his new role at Frost & Sullivan, Mr. Khan will be responsible
in expanding the team and working closely with the clients in the
country and region. As a Market research executive with extensive
pharmaceutical experience in managing business intelligence and sales
and marketing effectiveness functions, he will be working to increase
the visibility of the pharmaceutical team, and identifying more
effective ways to partner with companies to generate and evaluate
market data and implement their strategic plans, at both the brand and
corporate levels.

"I am making an exciting move in my career, where I will be
capitalizing on all my previous experiences to further add to Frost &
Sullivan's standing in Australia and to provide top value added
services to its pharmaceutical clients," Mr. Khan said.

Mr. Khan brings with him a rich 20 years of experience in the
Australian healthcare industry. Mr. Khan has previously lead Market
Research and Business Intelligence functions in multinational
companies such as Eli Lilly, Aventis and Wyeth.

Mr. Raja also said that it is an important move for our healthcare
business to include someone like Maz Khan. "He brings to our team a
wealth of local knowledge and exceptional skills which will strengthen
our partnerships and add clear value to the work we do in the
Pharmaceutical industry," he added.

"Frost & Sullivan's pharmaceutical & biotechnology group works
with leading multinational companies in Australia and has formed a
global team of experts to support our partners in the expansion of
their businesses. We have a strong commitment to increasing our
expertise in the pharmaceutical and biotechnology space globally, and
having Maz Khan on the team will further strengthen our local and
global pharmaceutical expertise and operations," says Ms. Rhenu
Bhuller, Global Vice President, Pharmaceuticals/ Biotechnology
Practice, Frost & Sullivan.

Frost & Sullivan Healthcare Practice has a team of more than 90
experienced analysts in Asia Pacific dedicated to research in the
pharmaceuticals, medical devices, biotechnology, healthcare IT markets
as well as emerging technology trends in the region.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with
clients to accelerate their growth. The company's TEAM Research,
Growth Consulting and Growth Team Membership empower clients to create
a growth-focused culture that generates, evaluates and implements
effective growth strategies. Frost & Sullivan employs over 45 years of
experience in partnering with Global 1000 companies, emerging
businesses and the investment community from more than 30 offices on
six continents. For more information about Frost & Sullivan's Growth
Partnerships, visit http://www.frost.com.

Frost & Sullivan
Corporate Communications - Healthcare, Asia Pacific
Jasminder Kaur
Did: +65 6890 0937
Mobile: +65 9062 7051
jkaur@frost.com
or
Corporate Communications - Healthcare, Asia Pacific
Shereen Gill
Did: +603 6204 5909
Mobile: +6017 617 8300
shereen.gill@frost.com
or
Australia office
Suite 1, Level 9
189 Kent Street
Sydney, NSW Australia
Tel: +61 (0)2 8247 9800
Fax: +61 (0)2 9252 8066

Copyright Business Wire 2008